Register a trial

Please note that the ANZCTR will be unattended on Friday 25th April due to the ANZAC Day public holiday. Submissions and updates will not be processed during that time.

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06671496




Registration number
NCT06671496
Ethics application status
Date submitted
31/10/2024
Date registered
4/11/2024

Titles & IDs
Public title
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Scientific title
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)
Secondary ID [1] 0 0
2024-513112-99-00
Secondary ID [2] 0 0
TAK-279-PsA-3002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Zasocitinib
Treatment: Drugs - Placebo

Experimental: Zasocitinib Dose A - Participants will receive zasocitinib Dose A, tablets, orally, once daily (QD) for up to Week 52.

Experimental: Zasocitinib Dose B - Participants will receive zasocitinib Dose B, tablets, orally, QD for up to Week 52.

Experimental: Placebo + Zasoctinib - Participants will receive placebo, orally, QD for up to Week 16, followed by zasoctinib Dose A or Dose B, orally, QD, from Week 16 up to Week 52.


Treatment: Drugs: Zasocitinib
Zasocitinib tablets.

Treatment: Drugs: Placebo
Zasocitinib matching placebo.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [1] 0 0
At Week 16
Secondary outcome [1] 0 0
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [1] 0 0
At Week 16
Secondary outcome [2] 0 0
Percentage of Participants Achieving PASI-75 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [2] 0 0
Baseline, at Week 16
Secondary outcome [3] 0 0
Percentage of Participants Achieving ACR50 Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [3] 0 0
At Week 16
Secondary outcome [4] 0 0
Change From Baseline in the HAQ-DI Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [4] 0 0
Baseline, at Week 16
Secondary outcome [5] 0 0
Percentage of Participants Achieving ACR70 Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [5] 0 0
At Week 16
Secondary outcome [6] 0 0
Change From Baseline in the Short Form-36 Health Survey Version 2.0 (SF-36 v2.0) Physical Component Summary (PCS) Score at Week 16 for Zasocitinib Dose A Compared to Placebo
Timepoint [6] 0 0
Baseline, at Week 16
Secondary outcome [7] 0 0
Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)- Fatigue Score at Week 16 for Zasocitinib Dose A Compared to Placebo
Timepoint [7] 0 0
Baseline, at Week 16
Secondary outcome [8] 0 0
Percentage of Participants Achieving LEI =0 (in Participants With a Baseline LEI >=1) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [8] 0 0
Baseline, at Week 16
Secondary outcome [9] 0 0
Change From Baseline in Individual Components of ACR Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [9] 0 0
Baseline, at Week 16
Secondary outcome [10] 0 0
Percentage of Participants Achieving Leeds Dactylitis Index (LDI) =0 (in Participants With a Baseline LDI >=1) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [10] 0 0
Baseline, at Week 16
Secondary outcome [11] 0 0
Percentage of Participants Achieving PASI-75 Response (in Participants With a Baseline >=3% BSA) at Week 8 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [11] 0 0
Baseline, at Week 8
Secondary outcome [12] 0 0
Percentage of Participants Achieving PASI-90 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [12] 0 0
Baseline, at Week 16
Secondary outcome [13] 0 0
Percentage of Participants Achieving PASI-100 Response (in Participants With a Baseline >=3% BSA) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [13] 0 0
Baseline, at Week 16
Secondary outcome [14] 0 0
Percentage of Participants Achieving ACR50 and PASI-100 Response (in Participants With a Baseline >=3% BSA) Simultaneously at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [14] 0 0
Baseline, at Week 16
Secondary outcome [15] 0 0
Percentage of Participants Achieving sPGA Response of Clear (0) or Almost Clear (1) With >=2-Point Decrease From Baseline (in Participants With a Baseline sPGA >=2) at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [15] 0 0
Baseline, at Week 16
Secondary outcome [16] 0 0
Percentage of Responders Achieving Minimal Clinically Important Differences (Reduction of >=0.35 From Baseline) in HAQ-DI Score From Baseline at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [16] 0 0
Baseline, at Week 16
Secondary outcome [17] 0 0
Change From Baseline in the SF-36 v2.0 Mental Component Summary (MCS) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [17] 0 0
Baseline, at Week 16
Secondary outcome [18] 0 0
Change From Baseline in Psoriatic Arthritis Impact of Disease-12 Items (PsAID-12) Total Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [18] 0 0
Baseline, at Week 16
Secondary outcome [19] 0 0
Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [19] 0 0
Baseline, at Week 16
Secondary outcome [20] 0 0
Change From Baseline in Disease Activity Score-28 (DAS28) (C-Reactive Protein) Score at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [20] 0 0
Baseline, at Week 16
Secondary outcome [21] 0 0
Change From Baseline in Physician's Global Assessment of Fingernail Psoriasis (PGA-F) Score in Participants With Psoriatic Nail Involvement (PGA-F Greater than [>] 0) From Baseline at Week 16 for Zasocitinib Dose A and B Compared to Placebo
Timepoint [21] 0 0
Baseline, at Week 16
Secondary outcome [22] 0 0
Change From Baseline in the SF-36 v2.0 PCS Score at Week 16 for Zasocitinib Dose B Compared to Placebo
Timepoint [22] 0 0
Baseline, at Week 16
Secondary outcome [23] 0 0
Change From Baseline in the FACIT- Fatigue Score at Week 16 for Zasocitinib Dose B Compared to Placebo
Timepoint [23] 0 0
Baseline, at Week 16

Eligibility
Key inclusion criteria
Age:

1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF).

Disease Characteristics:
2. The participant has had signs and symptoms consistent with PsA for at least 3 months.
3. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
4. The participant has active arthritis as shown by a minimum of >=3 tender joints in TJC68 and >=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits.
5. The participant has at least 1 active lesion of plaque PsO >=2 cm in diameter, or any nail or nail bed changes characteristic of PsO.

Medications for PsA:
6. The participant has had at least one of the following:

1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID), OR
2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD), OR
3. Biological disease-modifying antirheumatic drug (DMARD)-inadequate response (Bio-IR): Inadequate response to up to 2 biologic DMARDs.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
PsA and PsO:

1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/03/2025
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
26/01/2028
Actual
Sample size
Target
600
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Sunshine Coast University Private Hospital | Clinical Trials - Sippy Downs
Recruitment hospital [4] 0 0
The Queen Elizabeth Hospital | Rheumatology Department - Woodville South
Recruitment hospital [5] 0 0
Fiona Stanley Hospital - Palmyra Dc
Recruitment hospital [6] 0 0
Colin Bayliss Research and Teaching Unit - Victoria Park
Recruitment postcode(s) [1] 0 0
NSW 2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
QLD 4575 - Sippy Downs
Recruitment postcode(s) [4] 0 0
SA 5011 - Woodville South
Recruitment postcode(s) [5] 0 0
6961 - Palmyra Dc
Recruitment postcode(s) [6] 0 0
WA 6100 - Victoria Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Tucuman
Country [18] 0 0
Argentina
State/province [18] 0 0
San Juan
Country [19] 0 0
Brazil
State/province [19] 0 0
Minas Gerais
Country [20] 0 0
Brazil
State/province [20] 0 0
PR
Country [21] 0 0
Brazil
State/province [21] 0 0
RS
Country [22] 0 0
Brazil
State/province [22] 0 0
Sao Paulo
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
China
State/province [25] 0 0
Anhui
Country [26] 0 0
China
State/province [26] 0 0
Beijing
Country [27] 0 0
China
State/province [27] 0 0
Fujian
Country [28] 0 0
China
State/province [28] 0 0
Guandong
Country [29] 0 0
China
State/province [29] 0 0
Guangdong
Country [30] 0 0
China
State/province [30] 0 0
Henan
Country [31] 0 0
China
State/province [31] 0 0
Hubei
Country [32] 0 0
China
State/province [32] 0 0
Hunan Sheng
Country [33] 0 0
China
State/province [33] 0 0
Inner Mongolia Autonomous Region
Country [34] 0 0
China
State/province [34] 0 0
Jiangsu
Country [35] 0 0
China
State/province [35] 0 0
Jiangxi Sheng
Country [36] 0 0
China
State/province [36] 0 0
Jiangxi
Country [37] 0 0
China
State/province [37] 0 0
Pingxiang
Country [38] 0 0
China
State/province [38] 0 0
Shanghai
Country [39] 0 0
China
State/province [39] 0 0
Shanxi
Country [40] 0 0
China
State/province [40] 0 0
Sichuan
Country [41] 0 0
China
State/province [41] 0 0
Chengdu
Country [42] 0 0
China
State/province [42] 0 0
Guangzhou
Country [43] 0 0
China
State/province [43] 0 0
Wenzhou Shi
Country [44] 0 0
France
State/province [44] 0 0
Auvergne-Rhône-Alpes
Country [45] 0 0
France
State/province [45] 0 0
Haute Garonne
Country [46] 0 0
France
State/province [46] 0 0
Indre Et Loire
Country [47] 0 0
France
State/province [47] 0 0
Marne
Country [48] 0 0
France
State/province [48] 0 0
St Etienne
Country [49] 0 0
Germany
State/province [49] 0 0
Sachsen-Anhalt
Country [50] 0 0
Germany
State/province [50] 0 0
Sachsen
Country [51] 0 0
Germany
State/province [51] 0 0
Berlin
Country [52] 0 0
Germany
State/province [52] 0 0
Hamburg
Country [53] 0 0
Germany
State/province [53] 0 0
Herne
Country [54] 0 0
Japan
State/province [54] 0 0
Aichi
Country [55] 0 0
Japan
State/province [55] 0 0
Hokkaido
Country [56] 0 0
Japan
State/province [56] 0 0
Hukuoka
Country [57] 0 0
Japan
State/province [57] 0 0
Hyogo
Country [58] 0 0
Japan
State/province [58] 0 0
Mie-Ken
Country [59] 0 0
Japan
State/province [59] 0 0
Miyagi-Ken
Country [60] 0 0
Japan
State/province [60] 0 0
Miyagi
Country [61] 0 0
Japan
State/province [61] 0 0
Nagasaki
Country [62] 0 0
Japan
State/province [62] 0 0
Osaka
Country [63] 0 0
Japan
State/province [63] 0 0
Tokyo-To
Country [64] 0 0
Japan
State/province [64] 0 0
Tokyo
Country [65] 0 0
Poland
State/province [65] 0 0
Dolnoslaskie
Country [66] 0 0
Poland
State/province [66] 0 0
Kujawsko Pomorskie
Country [67] 0 0
Poland
State/province [67] 0 0
Malopolskie
Country [68] 0 0
Poland
State/province [68] 0 0
Pomorskie
Country [69] 0 0
Poland
State/province [69] 0 0
Warminsko-Mazurskie
Country [70] 0 0
Poland
State/province [70] 0 0
Wielkopolska
Country [71] 0 0
Poland
State/province [71] 0 0
Wybierz Województwo
Country [72] 0 0
Poland
State/province [72] 0 0
Czestochowa
Country [73] 0 0
Poland
State/province [73] 0 0
Lublin
Country [74] 0 0
Poland
State/province [74] 0 0
Wroclaw
Country [75] 0 0
Spain
State/province [75] 0 0
Cantabria
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Spain
State/province [77] 0 0
Pais Vasco
Country [78] 0 0
Spain
State/province [78] 0 0
Santa Cruz de Tenerife
Country [79] 0 0
Spain
State/province [79] 0 0
Sevilla
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Greater London
Country [81] 0 0
United Kingdom
State/province [81] 0 0
West Midlands
Country [82] 0 0
United Kingdom
State/province [82] 0 0
West Yorkshire
Country [83] 0 0
United Kingdom
State/province [83] 0 0
Harlow
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Oxford
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Stoke-on-Trent
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Takeda Contact
Address 0 0
Country 0 0
Phone 0 0
+1-877-825-3327
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06671496